glp-1 agonist. GLP-1R and Diabetes GLP-1 Agonists: A Comprehensive Overview
Description
Given the investigational nature of low-dose GLP-1 therapy for inflammation, identifying appropriate candidates requires careful clinical judgment and shared decision-making
The common ones include semaglutide (Ozempic, Wegovy), liraglutide (Victoza), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity) and exenatide (Byetta)
Eli Lilly , a competitor in the GLP-1 market, is also aiming to expand the use of its tirzepatide , which was approved for type 2 diabetes in 2021 under the brand name MOUNJARO and for weight loss as ZEPBOUND in late 2023
Patoulias D, Michailidis T
